This is a preclinical venture. The two companies will seek to discover a new class of small molecules that target the GCase enzyme.
There are no upfront payments to FOLD.
BIIB will fund all discovery, development, and commercialization and will reimburse FOLD for the cost of employees working on the project.
FOLD is eligible for development and regulatory milestones and "modest" royalties. (PR)